Latest News

20 February 2012

Starpharma Interim Report and Half-year Financial Results

Starpharma Holdings  today released its interim report and financial results for the half-year ended 31 December 2011.

Financial Results

  • Cash position at 31 December 2011 $49.0M
  • Net cash outflows from operations $3.9M
  • Net cash inflows from financing $33.8M
  • Reported loss $4.7M
Read more

1 February 2012

Starpharma’s dendrimers improve efficacy of docetaxel in animals

-  Starpharma's dendrimer-docetaxel formulation significantly more effective than leading cancer drug docetaxel (Taxotere®) in breast cancer model

 -  More than half (60%) of animals treated with Starpharma's dendrimer-docetaxel formulation had no evidence of tumour at 94 days whereas with docetaxel significant tumour regrowth was observed in all animals

-  Starpharma's dendrimer-docetaxel formulation improved water solubility by 5000-fold

Read more

11 January 2012

SPL receives FDA Special Protocol Assessment for BV Phase 3

Starpharma today announced that it has received final written agreement from the FDA on the design of its Phase 3 clinical studies of VivaGel® for the treatment of bacterial vaginosis (BV) under the FDA’s Special Protocol Assessment (SPA) scheme.

The SPA is a binding declaration from the FDA that the Phase 3 clinical study design, endpoints, statistical analyses, and other aspects of the planned studies are acceptable to support regulatory approval of the product.

Read more

19 December 2011

Starpharma's drug delivery program with Lilly advances

Starpharma today announced the advancement of its drug delivery collaboration with US pharmaceutical corporation Eli Lilly and Company.

Read more

In the media

14 February 2012

Herald Sun: In the Black

Herald Sun Journalist John Beveridge details how biotechnology companies are working to ‘fix many ailments’, with specific reference to promising results emerging from Starpharma’s diverse research portfolio.

The best thing about Starpharma is that it owns a genuine platform technology that is capable of spinning off multiple products across a range of different and highly lucrative areas.

It owns a forest of patents on dendrimers—tiny polymers which can be engineered to create many different results, such as making a drug water soluble or preventing the transmission of viruses and bacteria.

Chief executive Dr Jackie Fairley said the recent approval from the US Food and Drug Administration and European regulators for phase 3 trials of its VivaGel product later this year was a highly significant step in bringing the product to market.

10 February 2012

Bioshares Report: Starpharma Takes Aim at Docetaxel

This Bioshares analysis provides insight into promising advancements within the Biotech sector in 2012. Starpharma is recognised for achieving a significant rise in shareprice and reaching exciting milestones in the development and pending commercialisation of its diverse research portfolio.

 

Download: Bioshares Issue 442 (pdf file, 27kb)

8 February 2012

Australian Financial Review: Biotechs making a steady recovery

Australian Financial Review Journalist Brendon Lau investigates how Australian biotech companies are attracting the attention of local and international investors.

There is likely to be a sharp pick-up in interest in Australian biotechs this year as they move into their next phase of growth, which will pave the way for them to be taken over by global drug companies.

Most of the capital is expected to be invested in the Australian market as our biotech sector is considered to be the most mature in the region following the resounding success of the likes of Mesoblast, Acrux and Starpharma Holdings, which have put Australia on the global biotech stage.

Retail shareholders strongly oversubscribed for their entitlements at recent capital raisings by Alchemia, Phosphagenics and Starpharma – the latter two attracting new overseas professional and high net-worth investors.

12 January 2012

Australian Financial Review: Starpharma's VivaGel step closer to market

Australian Financial Review Journalist Carrie LaFrenz reports: Emerging biotech Starpharma Holdings has been given the tick of approval from the US Federal and Drug Administration on the design of its Phase 3 clinical studies for its key VivaGel product, taking it one step closer to market.

Starpharma has a number of promising technologies and has caught the attention of some large investors. UK-based M&G Investments took a 6.7 per cent stake following the successful $32 million placement in November.

Shareholder Updates

20 December 2011

Shareholder Update: December 2011

In this issue:

Starpharma raises $35m to advance pipeline

Starpharma signs with Ansell for condom coating

Putting a stop to stubborn BV: The VivaGel© solution

Clinical trials for VivaGel© gather pace

M&G invests $20 million

Dendrimers through the eyes of Professor Donald Tomalia

 

Download: Shareholder Update: December 2011 (pdf file, 628kb)

Read more

26 July 2011

Shareholder Update: July 2011

In this issue:

VivaGel® demonstrates efficacy in the treatment of bacterial vaginosis; Independent study finds link between bacterial vaginosis and HIV

Japanese VivaGel® condom deal secures second largest condom market in the world

Starpharma’s Priostar dendrimers improve bestselling herbicide

Drug delivery program delivers early-stage results in improving blockbuster chemo drug.

 

Download:  Shareholder Update: July 2011 ( pdf file, 1MB)

Read more

Sign up to receive news here

© Starpharma Holdings Limited 2011